Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: HIV Infections
Interventions: Tenofovir DF, Zidovudine, Stavudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Jacksonville, Florida + 2 more

Conditions: Impotence
Interventions: tadalafil, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Newport Beach, California + 7 more

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Acute Uncomplicated Diverticulitis
Interventions: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, Placebo, Metronidazole, Cefuroxime; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Asthma, Obesity
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Colchester, Vermont

Conditions: Genital Herpes
Interventions: Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more

Conditions: HCV Infection
Interventions: SOF, RBV, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more

Conditions: Obesity
Interventions: BMS-646256, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Depressive Episodes, Bipolar I Depression
Interventions: SEP-4199 CR; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2033
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 6 more

Conditions: Anemia of Chronic Kidney Disease
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 4 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Elbow Fracture
Interventions: Oxycodone with Acetaminophen, Bupivacaine 0.25%, Ropivacaine 0.20%; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 4 Years to 12 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate/Emtricitabine, Lopinavir/Ritonavir; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Denver, Colorado • Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 52
States / cities: Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more

Conditions: Obesity
Interventions: CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling; Behavioral · Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Macular Edema, Diabetic
Interventions: Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more

Conditions: HIV Infections
Interventions: LDMTX, Placebo, Folic acid; Drug · Dietary Supplement
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 40 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Overactive Bladder
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 95
States / cities: Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more

Conditions: Sickle Cell Disease
Interventions: IW-1701, Placebo; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Orange, California • Washington D.C., District of Columbia • Aventura, Florida + 23 more

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions: Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: TRx0237, Placebo; Drug
Lead sponsor: TauRx Therapeutics Ltd; Industry
Eligibility: Up to 79 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more

Conditions: Urinary Tract Infections, Catheter-Related Infections
Interventions: methenamine hippurate, Ciprofloxacin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated interferon alfa 2a; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more

Search by objective public record fields.

Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Lifestyle Modification and Liraglutide

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

Fesoterodine Flexible Dose Study

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

The CARDIOPROTECT Trial

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy